Results 231 to 240 of about 45,236 (264)
Some of the next articles are maybe not open access.
JAMA: The Journal of the American Medical Association, 1984
To the Editor.— We have reviewed the experience of a large cohort of outpatient recipients of allopurinol to estimate the frequency of serious toxic reactions caused by this drug. This study was derived from Group Health Cooperative of Puget Sound, a health maintenance organization that provides comprehensive medical care to its members. Prescriptions
Hershel Jick, David R. Perera
openaire +3 more sources
To the Editor.— We have reviewed the experience of a large cohort of outpatient recipients of allopurinol to estimate the frequency of serious toxic reactions caused by this drug. This study was derived from Group Health Cooperative of Puget Sound, a health maintenance organization that provides comprehensive medical care to its members. Prescriptions
Hershel Jick, David R. Perera
openaire +3 more sources
American Journal of Clinical Dermatology, 2010
Off-label use is common in dermatology, and is inevitable for rare cutaneous diseases such as perforating dermatosis. Allopurinol is traditionally considered to be a drug for hyperuricemia only, but the recent demonstration of its efficacy in congestive heart failure has spurred renewed interest in its application in other clinical specialties.
Tsen-Fang Tsai, Ting-Yu Yeh
openaire +3 more sources
Off-label use is common in dermatology, and is inevitable for rare cutaneous diseases such as perforating dermatosis. Allopurinol is traditionally considered to be a drug for hyperuricemia only, but the recent demonstration of its efficacy in congestive heart failure has spurred renewed interest in its application in other clinical specialties.
Tsen-Fang Tsai, Ting-Yu Yeh
openaire +3 more sources
Cochrane Database of Systematic Reviews, 2013
Allopurinol, a xanthine oxidase inhibitor, is considered one of the most effective urate-lowering drugs and is frequently used in the treatment of chronic gout.To assess the efficacy and safety of allopurinol compared with placebo and other urate-lowering therapies for treating chronic gout.We searched the Cochrane Central Register of Controlled Trials
Claire Bombardier +4 more
openaire +4 more sources
Allopurinol, a xanthine oxidase inhibitor, is considered one of the most effective urate-lowering drugs and is frequently used in the treatment of chronic gout.To assess the efficacy and safety of allopurinol compared with placebo and other urate-lowering therapies for treating chronic gout.We searched the Cochrane Central Register of Controlled Trials
Claire Bombardier +4 more
openaire +4 more sources
The Development of Allopurinol
Archives of Internal Medicine, 1985The Clinical Research Unit (CRU) program of the National Institutes of Health, developed in the late 1950s, proved to be an important innovation in the use of public funds to support medical research. The establishment of these units led to a material improvement in the quality, convenience, and feasibility of many types of investigation involving ...
openaire +3 more sources
Clinical Pharmacology & Therapeutics, 1978
A spectrophotometric assay for measuring allopurinol and oxipurinol has been developed which can detect as little as 5 × 10−8 M of each in serum and urine. With this assay, serum disappearance characteristics of intravenous and orally administered allopurinol have been investigated in man.
K, Hande, E, Reed, B, Chabner
openaire +2 more sources
A spectrophotometric assay for measuring allopurinol and oxipurinol has been developed which can detect as little as 5 × 10−8 M of each in serum and urine. With this assay, serum disappearance characteristics of intravenous and orally administered allopurinol have been investigated in man.
K, Hande, E, Reed, B, Chabner
openaire +2 more sources
Allopurinol and severe epilepsy [PDF]
Neurology, 1986 Forty-one epileptic and not hyperuricemic subjects, aged 2 to 54 years, had epileptic seizures, ranging from 1 to 220 weekly (mean = 21.3). All seizure types were represented. They were already medicated with two or three antiepileptic drugs with plasma drug concentrations maintained in therapeutic range.
Pasquale DeMarco, Piergiuseppe Zagnoni
openaire +2 more sources
Clinical Pharmacokinetics of Allopurinol
Clinical Pharmacokinetics, 1986Allopurinol is a widely used drug in the management of hyperuricaemia. It is rapidly and extensively absorbed following oral administration. The major and active metabolite, oxypurinol, is detected in the circulation within 15 minutes of allopurinol administration.
George A.C. Murrell, W. G. Rapeport
openaire +3 more sources
The allopurinol hypersensitivity syndrome
The Netherlands Journal of Medicine, 1998We describe a 61-year-old male patient who was treated with allopurinol and developed fever, a skin rash, eosinophilia and severe renal and liver dysfunction. We discuss the allopurinol hypersensitivity syndrome as a serious complication of the use of allopurinol, and briefly review the aetiology, prevention and treatment modalities.
Pluim, H.J. +2 more
openaire +4 more sources
The allopurinol hypersensitivity syndrome
Journal of the American Academy of Dermatology, 1979Hypersensitivity reactions to allopurinol, a drug commonly used in the treatment of hyperuricemia, are being reported with increasing frequency. Of thirty-eight patients reviewed herein (including seven from our hospital and thirty-one from a review of the literature), ten deaths (26%) were related to complications of allopurinol hypersensitivity ...
George P. Lupton, Richard B. Odom
openaire +3 more sources
1991
This is the first published case report with measurement of allopurinol and oxipurinol in a breast milk sample and a plasma sample of a breast fed infant.
Irmingard Kamilli +3 more
openaire +3 more sources
This is the first published case report with measurement of allopurinol and oxipurinol in a breast milk sample and a plasma sample of a breast fed infant.
Irmingard Kamilli +3 more
openaire +3 more sources